For example, antibodies to the programmed death ligand-1 (PD-L1) are FDA-approved in gastric, colorectal, renal, and triple-negative breast cancer, melanoma, and NSCLC [28,29,30]. This evidence concerns the gene CD274 and triple-negative breast carcinoma.